US drugmaker Eli Lilly has struck a deal with domestic drug giant Cipla Ltd to widen the reach of its blockbuster weight loss drug tirzepatide, doubling down on India’s booming market ahead of an impending wave of anti-obesity generics.

Eli Lilly, which already sells its weight loss drug in India under the Mounjaro brand, will supply the drug to Cipla, which will promote and retail it under a second brand name, Yurpeak. Both drugs will cost the same. Also Read | Novo Nordisk launches weight loss drug Wegovy priced at ₹17,345 per month

The idea of roping in Cipla is to penetrate markets which are currently beyond Eli Lilly's reach. The partnership also marks Cipla’s entry into the fast-growing weight loss drug market in India. India’s weight-loss drug market is projected to grow ra

See Full Page